Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 22.04.2024 1 Ann Surg Oncol 1 BMC Cancer 1 BMJ 3 Br J Cancer 2 Breast Cancer 1 Breast Cancer (Auckl) 4 Breast Cancer (Dove Med Press) 5 Breast Cancer Res 3 Breast Cancer Res Treat 1 Cancer 1 Cancer Epidemiol Biomarkers Prev 6 Clin Breast Cancer 1 Clin Cancer Res 1 Eur J Cancer 1 Eur J Surg Oncol 3 Int J Radiat Oncol Biol Phys 1 J Nucl Med 3 Lancet 1 Mod Pathol 2 NPJ Breast Cancer 2 Oncogene 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. PARVEZ E, Bogach J, Kirkwood D, Pond G, et al
   Immigration Status and Breast Cancer Surgery Quality of Care Metrics: A Population-Level Analysis.
   Ann Surg Oncol. 2024 Apr 18. doi: 10.1245/s10434-024-15250.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. GILL J, Yendamuri K, Chatterjee U, Yao S, et al
   Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.
   BMC Cancer. 2024;24:461.
   PubMed         Abstract available
   
   

   
   BMJ

3. WISE J
   Breast cancer: Inaction on inequalities has led to unequal progress, say experts.
   BMJ. 2024;385:q854.
   PubMed        
   
   

   
   Br J Cancer

4. SHEN F, Jiang G, Philips S, Cantor E, et al
   Germline predictors for bevacizumab induced hypertensive crisis in ECOG-ACRIN 5103 and BEATRICE.
   Br J Cancer. 2024;130:1348-1355.
   PubMed         Abstract available
   
   
5. BRAUN M, Piasecka D, Sadej R, Romanska HM, et al
   FGFR4-driven plasticity in breast cancer progression and resistance to therapy.
   Br J Cancer. 2024 Apr 17. doi: 10.1038/s41416-024-02658.
   PubMed         Abstract available
   
   
6. CHANG CY, Jones BL, Hincapie-Castillo JM, Park H, et al
   Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.
   Br J Cancer. 2024 Apr 18. doi: 10.1038/s41416-024-02680.
   PubMed         Abstract available
   
   

   
   Breast Cancer

7. ZHANG HP, Jiang RY, Zhu JY, Sun KN, et al
   PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
   Breast Cancer. 2024 Apr 17. doi: 10.1007/s12282-024-01567.
   PubMed         Abstract available
   
   
8. ROUSSET-JABLONSKI C, Lortal B, Lantheaume S, Arnould L, et al
   French national survey on breast cancer care: caregiver and patient views.
   Breast Cancer. 2024 Apr 18. doi: 10.1007/s12282-024-01576.
   PubMed         Abstract available
   
   

   
   Breast Cancer (Auckl)

9. AURELL C, Haidar A, Giglio D
   Follow-up Routines Matter for Adherence to Endocrine Therapy in the Adjuvant Setting of Breast Cancer.
   Breast Cancer (Auckl). 2024;18:11782234241240171.
   PubMed         Abstract available
   
   

   
   Breast Cancer (Dove Med Press)

10. YE M, Xu H, Ding J, Jiang L, et al
    Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review.
    Breast Cancer (Dove Med Press). 2024;16:181-197.
    PubMed         Abstract available
    
    
11. SYAHRUDDIN FI, Prihantono, Muis M
    Serum HER2 Level Predicts Therapeutic Efficacy and Prognosis in Advanced Breast Cancer Patients [Letter].
    Breast Cancer (Dove Med Press). 2024;16:221-222.
    PubMed        
    
    
12. CHEN Y, Li WX, Wu JH, Chen GH, et al
    Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.
    Breast Cancer (Dove Med Press). 2024;16:223-231.
    PubMed         Abstract available
    
    
13. MA S, Hao R, Lu YW, Wang HP, et al
    Identification and Validation of Novel Metastasis-Related Immune Gene Signature in Breast Cancer.
    Breast Cancer (Dove Med Press). 2024;16:199-219.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

14. 
    Meeting Abstracts from the British Society of Breast Radiology annual scientific meeting 2023.
    Breast Cancer Res. 2024;26.
    PubMed        
    
    
15. ZHANG N, Huang Y, Wang G, Xiang Y, et al
    Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer.
    Breast Cancer Res. 2024;26:64.
    PubMed         Abstract available
    
    
16. BAE SJ, Kook Y, Jang JS, Baek SH, et al
    Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
    Breast Cancer Res. 2024;26:65.
    PubMed         Abstract available
    
    
17. SALEMBIER R, De Haes C, Bellemans J, Demeyere K, et al
    Chitin-mediated blockade of chitinase-like proteins reduces tumor immunosuppression, inhibits lymphatic metastasis and enhances anti-PD-1 efficacy in complementary TNBC models.
    Breast Cancer Res. 2024;26:63.
    PubMed         Abstract available
    
    
18. BAE SJ, Chun JW, Lee SB, Ryu JM, et al
    Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study.
    Breast Cancer Res. 2024;26:66.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

19. FERNANDEZ-GONZALEZ S, Falo C, Pla MJ, Campos M, et al
    Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival-a propensity score cohort study.
    Breast Cancer Res Treat. 2024 Apr 18. doi: 10.1007/s10549-024-07274.
    PubMed         Abstract available
    
    
20. BALTUSSEN JC, Mooijaart SP, Vulink AJE, Houtsma D, et al
    Tolerability and effectiveness of palbociclib in older women with metastatic breast cancer.
    Breast Cancer Res Treat. 2024 Apr 16. doi: 10.1007/s10549-024-07312.
    PubMed         Abstract available
    
    
21. TAN CF, Wang J, Zhong XR, Dai ZL, et al
    Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
    Breast Cancer Res Treat. 2024 Apr 15. doi: 10.1007/s10549-024-07249.
    PubMed         Abstract available
    
    

    
    Cancer

22. BERNSTEIN-MOLHO R, Shhada NA, Laitman Y, Netzer I, et al
    Targeted genotyping for recurring variants in cancer susceptibility genes in non-Ashkenazi Jewish patients with breast cancer diagnosed >/=50 years.
    Cancer. 2024 Apr 17. doi: 10.1002/cncr.35329.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

23. COLLISTER JA, Liu X, Littlejohns TJ, Cuzick J, et al
    Assessing the value of incorporating a polygenic risk score with non-genetic factors for predicting breast cancer diagnosis in the UK Biobank.
    Cancer Epidemiol Biomarkers Prev. 2024.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

24. PAN W, Cheng H, Zhang J, Yang Z, et al
    The FGFR2 Variant rs13387042 is Associated With Breast Cancer Risk: A Meta-Analysis and Systematic Review.
    Clin Breast Cancer. 2024 Mar 15:S1526-8209(24)00082.
    PubMed         Abstract available
    
    
25. CORPUZ GS, Kim DK, Kim IE Jr, Rohde CH, et al
    Existing Psychiatric Diagnoses Among Breast Cancer Patients Interact with Outcomes After Autologous and Implant-Based Bilateral Breast Reconstruction: A Propensity Score Matched Analysis.
    Clin Breast Cancer. 2024 Mar 24:S1526-8209(24)00096.
    PubMed         Abstract available
    
    
26. YADAV BS, Dey T
    Hypofractionation for Regional Nodal Irradiation in Breast Cancer: Best of Both the Worlds.
    Clin Breast Cancer. 2024 Mar 14:S1526-8209(24)00080.
    PubMed         Abstract available
    
    
27. DOWNS-CANNER S, Weiss A
    Systemic Therapy Advances for HER2-Positive and Triple Negative Breast Cancer: What the Surgeon Needs to Know.
    Clin Breast Cancer. 2024 Mar 13:S1526-8209(24)00077.
    PubMed         Abstract available
    
    
28. HU Y, Zhu Y, Shi J, Wei X, et al
    Plasma Thioredoxin Reductase as a Potential Diagnostic Biomarker for Breast Cancer.
    Clin Breast Cancer. 2024 Mar 15:S1526-8209(24)00081.
    PubMed         Abstract available
    
    
29. ZHANG M, Zha H, Pan J, Liu X, et al
    Development of an Ultrasound-based Nomogram for Predicting Pathologic Complete Response and Axillary Response in Node-Positive Patients with Triple- Negative Breast Cancer.
    Clin Breast Cancer. 2024 Mar 23:S1526-8209(24)00098.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

30. IWASE T, Cohen EN, Gao H, Alexander A, et al
    Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2947.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

31. GUERINI-ROCCO E, Bellerba F, Concardi A, Taormina SV, et al
    Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ.
    Eur J Cancer. 2024;203:114063.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

32. APOSTOLOVA C, Ferroum A, Alhassan B, Prakash I, et al
    Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
    Eur J Surg Oncol. 2024;50:108324.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

33. PATEL TA, Jain B, Vapiwala N, Chino F, et al
    Trends in Utilization and Medicare Spending on Short-Course Radiotherapy for Breast and Prostate Cancer: An Episode-Based Analysis from 2015-2019.
    Int J Radiat Oncol Biol Phys. 2023 Dec 8:S0360-3016(23)08173.
    PubMed         Abstract available
    
    
34. ROGE M, Kirova Y, Leveque E, Guigo M, et al
    Impact of radiation therapy modalities on loco-regional control in inflammatory breast cancer.
    Int J Radiat Oncol Biol Phys. 2024 Apr 13:S0360-3016(24)00506.
    PubMed         Abstract available
    
    
35. KIM E, Yoo JS, Kim YJ, Joo J, et al
    Toxicity evaluation of dose-escalation in hypofractionated regional nodal irradiation for breast cancer: a retrospective study.
    Int J Radiat Oncol Biol Phys. 2024 Apr 15:S0360-3016(24)00513.
    PubMed         Abstract available
    
    

    
    J Nucl Med

36. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    PubMed         Abstract available
    
    

    
    Lancet

37. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    PubMed        
    
    
38. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    PubMed        
    
    
39. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    PubMed        
    
    

    
    Mod Pathol

40. DE SCHEPPER M, Koorman T, Richard F, Christgen M, et al
    Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European Lobular Breast Cancer Consortium.
    Mod Pathol. 2024 Apr 17:100497. doi: 10.1016/j.modpat.2024.100497.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

41. MORGANTI S, Jin Q, Vincuilla J, Buehler R, et al
    Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
    NPJ Breast Cancer. 2024;10:28.
    PubMed         Abstract available
    
    
42. LIEFAARD MC, van der Voort A, van Seijen M, Thijssen B, et al
    Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
    NPJ Breast Cancer. 2024;10:29.
    PubMed         Abstract available
    
    

    
    Oncogene

43. CHEN X, Ma C, Li Y, Liang Y, et al
    COL5A1 promotes triple-negative breast cancer progression by activating tumor cell-macrophage crosstalk.
    Oncogene. 2024 Apr 12. doi: 10.1038/s41388-024-03030.
    PubMed         Abstract available
    
    
44. ZHOU Z, Zheng X, Zhao J, Yuan A, et al
    ULK1-dependent phosphorylation of PKM2 antagonizes O-GlcNAcylation and regulates the Warburg effect in breast cancer.
    Oncogene. 2024 Apr 17. doi: 10.1038/s41388-024-03035.
    PubMed         Abstract available
    
    

    
    PLoS One

45. BAHCACI U, Atasavun Uysal S, Erdogan Iyigun Z, Ordu C, et al
    Progressive relaxation training in patients with breast cancer receiving aromatase inhibitor therapy-randomized controlled trial.
    PLoS One. 2024;19:e0301020.
    PubMed         Abstract available
    
    
46. ABIDI O, Abdelkafi-Koubaa Z, Bettaieb-Dridi I, Toumi L, et al
    Pistacia lentiscus L. revealed in vitro anti-proliferative activity on MCF-7 breast cancer cells and in vivo anti-mammary cancer effect on C57BL/6 mice through necrosis, anti-inflammatory and antioxidant enhancements.
    PLoS One. 2024;19:e0301524.
    PubMed         Abstract available
    
    
47. ERDOGAN C, Suer I, Kaya M, Ozturk S, et al
    Bioinformatics analysis of the potentially functional circRNA-miRNA-mRNA network in breast cancer.
    PLoS One. 2024;19:e0301995.
    PubMed         Abstract available
    
    
48. ALLANA A, Shamsi U, Rashid Y, Khan FR, et al
    Oral mucositis & oral health related quality of life in women undergoing chemotherapy for breast cancer in Karachi, Pakistan: A multicenter hospital based cross-sectional study.
    PLoS One. 2024;19:e0295456.
    PubMed         Abstract available
    
    
49. EUM DY, Jeong M, Park SY, Kim J, et al
    AM-18002, a derivative of natural anmindenol A, enhances radiosensitivity in mouse breast cancer cells.
    PLoS One. 2024;19:e0296989.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.